{"brief_title": "ALIMTA Plus Carboplatin as Front-Line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Phase 2 Clinical Trial.", "brief_summary": "The purpose of this study is to evaluate the effects (good and bad) of LY231514 (ALIMTA) and Carboplatin on you and your non-small cell lung cancer.", "condition": "Carcinoma, Non-Small-Cell Lung", "intervention_type": "Drug", "intervention_name": "Carboplatin", "criteria": "Inclusion Criteria: - You have a diagnosis of non-small cell lung cancer. - You have received no prior chemotherapy. - You have at least one measurable lesion. - You have an adequate performance status. - You are at least 18 years of age. Exclusion Criteria: - You have previously received chemotherapy for your lung cancer. - You have received radiation within the last 30 days. - You have active infection or other serious condition. - You have brain metastasis. - You have recently lost a significant amount of weight.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00051493.xml"}